BIOMAT Database Logo BIOMAT Database Logo

Comparative studies of glycoprotein Ib in heparin coated and nonheparin coated extracorporeal circulation circuits. 1998

I Hioki, and I Yada, and M Nishikawa, and Y Shomura, and B P Cruz, and K Onoda, and K Tani, and T Shimono, and H Shinpo
Department of Thoracic and Cardiovascular Surgery, Mie University School of Medicine, Tsu, Japan.

Contact between blood and artificial materials has various effects on blood. Impairment of platelet function is an especially important and well known effect, but its precise mechanism is not clearly understood. The authors constructed a circulation model to investigate the effect of extracorporeal circulation on platelet membrane glycoproteins (GPs), especially GP Ib, and to compare the changes in GP Ib in heparin coated (group C) and nonheparin coated (group N) circuits. As determined by flow cytometry, GP Ib in both groups decreased on initiating circulation, but the decrease in group N was significantly larger than that in group C. There was no observed change in GP IIb/IIIa levels in either group. The extent of shear stress induced platelet aggregation significantly decreased during circulation in both groups. Decreases in the extent of shear stress induced platelet aggregation were significantly less with the use of heparin coated circuits. In addition, the amount of GP Ib in the high speed pellet decreased progressively during circulation in both groups. In contrast, the amount of GP Ib in the Triton insoluble (low speed) pellet increased dramatically during circulation. However, expression of GP Ib in the Triton soluble platelet fraction was low in both groups. From the results, it was concluded that the cause of the decrease in platelet function during extracorporeal circulation is attributable to the internalization of GP Ib from the platelet surface inside the platelet. It also can be said that a heparin coated circuit is one effective means of controlling this change.

UI MeSH Term Description Entries
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D004867 Equipment Design Methods and patterns of fabricating machines and related hardware. Design, Equipment,Device Design,Medical Device Design,Design, Medical Device,Designs, Medical Device,Device Design, Medical,Device Designs, Medical,Medical Device Designs,Design, Device,Designs, Device,Designs, Equipment,Device Designs,Equipment Designs
D005112 Extracorporeal Circulation Diversion of blood flow through a circuit located outside the body but continuous with the bodily circulation. Circulation, Extracorporeal,Circulations, Extracorporeal,Extracorporeal Circulations
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D019038 Platelet Glycoprotein GPIb-IX Complex Platelet membrane glycoprotein complex essential for normal platelet adhesion and clot formation at sites of vascular injury. It is composed of three polypeptides, GPIb alpha, GPIb beta, and GPIX. Glycoprotein Ib functions as a receptor for von Willebrand factor and for thrombin. Congenital deficiency of the GPIb-IX complex results in Bernard-Soulier syndrome. The platelet glycoprotein GPV associates with GPIb-IX and is also absent in Bernard-Soulier syndrome. Antigens, CD42a,Antigens, CD42b,Antigens, CD42c,Antigens, CD42d,CD42a Antigens,CD42b Antigens,CD42c Antigens,CD42d Antigens,Platelet Membrane Glycoprotein IX,Platelet Membrane Glycoprotein Ib,Platelet Membrane Glycoprotein V,CD42a Antigen,CD42b Antigen,CD42c Antigen,CD42d Antigen,Glycoprotein Ib,Glycoprotein Ib alpha,Glycoprotein Ib beta,Glycoprotein Ib-IX Complex,Platelet Glycoprotein IX,Antigen, CD42a,Antigen, CD42b,Antigen, CD42c,Antigen, CD42d,Glycoprotein Ib IX Complex,Platelet Glycoprotein GPIb IX Complex

Related Publications

I Hioki, and I Yada, and M Nishikawa, and Y Shomura, and B P Cruz, and K Onoda, and K Tani, and T Shimono, and H Shinpo
Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits (2nd version). The European Working Group on heparin coated extracorporeal circulation circuits.
April 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
I Hioki, and I Yada, and M Nishikawa, and Y Shomura, and B P Cruz, and K Onoda, and K Tani, and T Shimono, and H Shinpo
Biocompatibility in heparin-coated extracorporeal circuits.
May 1996, Perfusion,
I Hioki, and I Yada, and M Nishikawa, and Y Shomura, and B P Cruz, and K Onoda, and K Tani, and T Shimono, and H Shinpo
Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits.
April 1991, The Journal of thoracic and cardiovascular surgery,
I Hioki, and I Yada, and M Nishikawa, and Y Shomura, and B P Cruz, and K Onoda, and K Tani, and T Shimono, and H Shinpo
Descending thoracic aortic aneurysm repair with the aid of partial cardiopulmonary bypass: heparin-coated circuits versus nonheparin-coated circuits.
April 2005, Artificial organs,
I Hioki, and I Yada, and M Nishikawa, and Y Shomura, and B P Cruz, and K Onoda, and K Tani, and T Shimono, and H Shinpo
Impact of Heparin- or Nonheparin-Coated Circuits on Platelet Function in Pediatric Cardiac Surgery.
April 2019, The Annals of thoracic surgery,
I Hioki, and I Yada, and M Nishikawa, and Y Shomura, and B P Cruz, and K Onoda, and K Tani, and T Shimono, and H Shinpo
Specific complement inhibition with heparin-coated extracorporeal circuits.
April 1996, The Annals of thoracic surgery,
I Hioki, and I Yada, and M Nishikawa, and Y Shomura, and B P Cruz, and K Onoda, and K Tani, and T Shimono, and H Shinpo
Heparin-coated versus non-coated surfaces for extracorporeal circulation.
November 1991, The International journal of artificial organs,
I Hioki, and I Yada, and M Nishikawa, and Y Shomura, and B P Cruz, and K Onoda, and K Tani, and T Shimono, and H Shinpo
Biomaterial-dependent blood activation during simulated extracorporeal circulation: a study of heparin-coated and uncoated circuits.
December 1997, The Thoracic and cardiovascular surgeon,
I Hioki, and I Yada, and M Nishikawa, and Y Shomura, and B P Cruz, and K Onoda, and K Tani, and T Shimono, and H Shinpo
Heparin-coated extracorporeal circulation systems in heart surgery.
November 2009, Recent patents on cardiovascular drug discovery,
I Hioki, and I Yada, and M Nishikawa, and Y Shomura, and B P Cruz, and K Onoda, and K Tani, and T Shimono, and H Shinpo
Complement activation during extracorporeal circulation. In vitro comparison of Duraflo II heparin-coated and uncoated oxygenator circuits.
September 1993, The Journal of thoracic and cardiovascular surgery,
Copied contents to your clipboard!